All news

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base.

• Annual revenue of €12 million (+14%) • Operating income close to breakeven • Reduction in net loss

Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que la Cour d’appel du Deleware (United States Court of Appeals for the third circuit) a décidé, dans un jugement rendu le 19 mars 2025, de confirmer la décision rendue en première instance et déboutant le groupe Spineway de sa demande d’exécution de la sentence arbitrale rendue à Genève qui faisait droit à la demande au fond de Spineway.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 2025 edition of the Arab Health trade fair, which was held at the Dubai World Trade Centre from January 27 to 30, 2025. This unmissable event for the medical sector in the Middle East offered Spineway the chance to strengthen its presence in the region and expand its distribution network.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is reporting annual revenue of €11.9 million in FY 2024, representing organic growth of 14% (excluding changes in the scope of consolidation) compared with FY 2023. This acceleration benefited from the successful integration of the Distimp and Spine Innovations acquisitions, which have strengthened the Group’s premium ranges and boosted sales in this segment.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has obtained approvals for its ACIFBOX, VEOS, KAPHORN and TWIN PEAKS ranges in Vietnam. Following this approval, initial orders have been placed, confirming the growing interest in Spineway products in the region.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, held a webinar on Thursday, December 5, during which Stéphane Le Roux, CEO of Spineway, reviewed the Group’s latest developments and confirmed its roadmap for the coming years.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that the Board of Directors of Spineway (the “Company”) decided at its meeting of December 4, 2024, acting on a delegation of authority granted by the Combined General Meeting of March 25, 2024, under the terms of its twenty-third resolution, to carry out a capital reduction motivated by losses through a reduction in the par value of its shares.

The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the Group’s ESP cervical and lumbar prostheses. These events also enabled the Group's distributors to provide ongoing training and support for their users.